Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berinert P for acute abdominal or facial hereditary angioedema attacks
2004-001186-17Phase 3Completed
- Sponsor
- CSL Behring
- Start
- May 2005
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of c1-esterase inhibitor in hereditary angioedema (HAE) (3 arms), sponsored by CSL Behring. Primary endpoint: Time to onset of relief from the evaluated attack. Started May 2005; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on 2004-001186-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001186-17.